Hemostemix (TSE:HEM) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Hemostemix Inc. has entered into a manufacturing partnership with CytoImmune Therapeutics to produce ACP-01, a cell therapy for severe arterial diseases, in a cutting-edge facility in Puerto Rico. Additionally, Hemostemix has secured $1.8 million in financing, with CytoImmune investing $1.37 million, signifying a strong commitment to the advancement of cell therapy. This strategic move aims to increase production and sales, offering a lifeline to patients facing chronic pain and potential limb amputation.
For further insights into TSE:HEM stock, check out TipRanks’ Stock Analysis page.
